Bafna Pharmaceuticals Limited (BAFNAPH.NS) Stock Competitors & Peer Comparison
See (BAFNAPH.NS) competitors and their performances in Stock Market.
Peer Comparison Table: Drug Manufacturers - Specialty & Generic Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| BAFNAPH.NS | ₹188.00 | +6.61% | 4.6B | 41.36 | ₹4.69 | N/A |
| SUNPHARMA.NS | ₹1,778.40 | -0.21% | 4.3T | 37.45 | ₹47.76 | +0.92% |
| SUNPHARMA.BO | ₹1,774.60 | -0.75% | 4.3T | 39.31 | ₹45.50 | +0.92% |
| DIVISLAB.NS | ₹6,750.00 | +1.92% | 1.7T | 67.44 | ₹96.70 | +0.46% |
| DIVISLAB.BO | ₹6,742.05 | +1.76% | 1.7T | 67.39 | ₹96.70 | +0.46% |
| TORNTPHARM.BO | ₹4,471.70 | +1.00% | 1.5T | 69.75 | ₹63.25 | +0.34% |
| TORNTPHARM.NS | ₹4,472.80 | +1.17% | 1.5T | 68.80 | ₹64.10 | +0.34% |
| ZYDUSLIFE.NS | ₹1,103.60 | +1.34% | 1.1T | 21.71 | ₹50.09 | +1.01% |
| ZYDUSLIFE.BO | ₹1,102.90 | +1.46% | 1.1T | 21.71 | ₹50.09 | +1.01% |
| DRREDDY.BO | ₹1,264.15 | -1.07% | 1.1T | 18.81 | ₹67.84 | +0.63% |
Stock Comparison
BAFNAPH.NS vs SUNPHARMA.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SUNPHARMA.NS has a market cap of 4.3T. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SUNPHARMA.NS trades at ₹1,778.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SUNPHARMA.NS's P/E ratio is 37.45. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SUNPHARMA.NS's ROE of +0.15%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SUNPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SUNPHARMA.NS's competition here
BAFNAPH.NS vs SUNPHARMA.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SUNPHARMA.BO has a market cap of 4.3T. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SUNPHARMA.BO trades at ₹1,774.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SUNPHARMA.BO's P/E ratio is 39.31. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SUNPHARMA.BO's ROE of +0.15%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SUNPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SUNPHARMA.BO's competition here
BAFNAPH.NS vs DIVISLAB.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, DIVISLAB.NS has a market cap of 1.7T. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while DIVISLAB.NS trades at ₹6,750.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas DIVISLAB.NS's P/E ratio is 67.44. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to DIVISLAB.NS's ROE of +0.17%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to DIVISLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check DIVISLAB.NS's competition here
BAFNAPH.NS vs DIVISLAB.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, DIVISLAB.BO has a market cap of 1.7T. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while DIVISLAB.BO trades at ₹6,742.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas DIVISLAB.BO's P/E ratio is 67.39. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to DIVISLAB.BO's ROE of +0.17%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to DIVISLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check DIVISLAB.BO's competition here
BAFNAPH.NS vs TORNTPHARM.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, TORNTPHARM.BO has a market cap of 1.5T. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while TORNTPHARM.BO trades at ₹4,471.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas TORNTPHARM.BO's P/E ratio is 69.75. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to TORNTPHARM.BO's ROE of +0.27%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to TORNTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check TORNTPHARM.BO's competition here
BAFNAPH.NS vs TORNTPHARM.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, TORNTPHARM.NS has a market cap of 1.5T. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while TORNTPHARM.NS trades at ₹4,472.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas TORNTPHARM.NS's P/E ratio is 68.80. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to TORNTPHARM.NS's ROE of +0.27%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to TORNTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check TORNTPHARM.NS's competition here
BAFNAPH.NS vs ZYDUSLIFE.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, ZYDUSLIFE.NS has a market cap of 1.1T. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while ZYDUSLIFE.NS trades at ₹1,103.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas ZYDUSLIFE.NS's P/E ratio is 21.71. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to ZYDUSLIFE.NS's ROE of +0.20%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to ZYDUSLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check ZYDUSLIFE.NS's competition here
BAFNAPH.NS vs ZYDUSLIFE.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, ZYDUSLIFE.BO has a market cap of 1.1T. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while ZYDUSLIFE.BO trades at ₹1,102.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas ZYDUSLIFE.BO's P/E ratio is 21.71. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to ZYDUSLIFE.BO's ROE of +0.20%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to ZYDUSLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check ZYDUSLIFE.BO's competition here
BAFNAPH.NS vs DRREDDY.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, DRREDDY.BO has a market cap of 1.1T. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while DRREDDY.BO trades at ₹1,264.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas DRREDDY.BO's P/E ratio is 18.81. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to DRREDDY.BO's ROE of +0.12%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to DRREDDY.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check DRREDDY.BO's competition here
BAFNAPH.NS vs DRREDDY.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, DRREDDY.NS has a market cap of 1.1T. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while DRREDDY.NS trades at ₹1,266.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas DRREDDY.NS's P/E ratio is 24.83. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to DRREDDY.NS's ROE of +0.12%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to DRREDDY.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check DRREDDY.NS's competition here
BAFNAPH.NS vs LUPIN.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, LUPIN.NS has a market cap of 1T. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while LUPIN.NS trades at ₹2,264.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas LUPIN.NS's P/E ratio is 19.38. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to LUPIN.NS's ROE of +0.28%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to LUPIN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check LUPIN.NS's competition here
BAFNAPH.NS vs LUPIN.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, LUPIN.BO has a market cap of 1T. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while LUPIN.BO trades at ₹2,265.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas LUPIN.BO's P/E ratio is 23.87. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to LUPIN.BO's ROE of +0.28%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to LUPIN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check LUPIN.BO's competition here
BAFNAPH.NS vs MANKIND.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, MANKIND.NS has a market cap of 973.4B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while MANKIND.NS trades at ₹2,385.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas MANKIND.NS's P/E ratio is 50.97. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to MANKIND.NS's ROE of +0.13%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to MANKIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check MANKIND.NS's competition here
BAFNAPH.NS vs MANKIND.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, MANKIND.BO has a market cap of 970.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while MANKIND.BO trades at ₹2,381.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas MANKIND.BO's P/E ratio is 50.79. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to MANKIND.BO's ROE of +0.13%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to MANKIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check MANKIND.BO's competition here
BAFNAPH.NS vs AUROPHARMA.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, AUROPHARMA.BO has a market cap of 843.2B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while AUROPHARMA.BO trades at ₹1,460.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas AUROPHARMA.BO's P/E ratio is 24.65. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to AUROPHARMA.BO's ROE of +0.10%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to AUROPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check AUROPHARMA.BO's competition here
BAFNAPH.NS vs AUROPHARMA.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, AUROPHARMA.NS has a market cap of 835.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while AUROPHARMA.NS trades at ₹1,458.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas AUROPHARMA.NS's P/E ratio is 24.04. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to AUROPHARMA.NS's ROE of +0.10%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to AUROPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check AUROPHARMA.NS's competition here
BAFNAPH.NS vs LAURUSLABS.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, LAURUSLABS.NS has a market cap of 758.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while LAURUSLABS.NS trades at ₹1,421.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas LAURUSLABS.NS's P/E ratio is 89.87. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to LAURUSLABS.NS's ROE of +0.19%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to LAURUSLABS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check LAURUSLABS.NS's competition here
BAFNAPH.NS vs LAURUSLABS.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, LAURUSLABS.BO has a market cap of 758.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while LAURUSLABS.BO trades at ₹1,418.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas LAURUSLABS.BO's P/E ratio is 89.86. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to LAURUSLABS.BO's ROE of +0.19%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to LAURUSLABS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check LAURUSLABS.BO's competition here
BAFNAPH.NS vs ALKEM.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, ALKEM.NS has a market cap of 640.4B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while ALKEM.NS trades at ₹5,358.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas ALKEM.NS's P/E ratio is 27.79. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to ALKEM.NS's ROE of +0.18%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to ALKEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check ALKEM.NS's competition here
BAFNAPH.NS vs ALKEM.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, ALKEM.BO has a market cap of 639.9B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while ALKEM.BO trades at ₹5,361.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas ALKEM.BO's P/E ratio is 27.77. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to ALKEM.BO's ROE of +0.18%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to ALKEM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check ALKEM.BO's competition here
BAFNAPH.NS vs GLENMARK.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, GLENMARK.BO has a market cap of 614.8B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while GLENMARK.BO trades at ₹2,214.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas GLENMARK.BO's P/E ratio is 45.11. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to GLENMARK.BO's ROE of +0.14%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to GLENMARK.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check GLENMARK.BO's competition here
BAFNAPH.NS vs GLENMARK.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, GLENMARK.NS has a market cap of 614.2B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while GLENMARK.NS trades at ₹2,212.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas GLENMARK.NS's P/E ratio is 45.05. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to GLENMARK.NS's ROE of +0.14%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to GLENMARK.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check GLENMARK.NS's competition here
BAFNAPH.NS vs IPCALAB.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, IPCALAB.NS has a market cap of 418.5B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while IPCALAB.NS trades at ₹1,639.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas IPCALAB.NS's P/E ratio is 36.66. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to IPCALAB.NS's ROE of +0.15%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to IPCALAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check IPCALAB.NS's competition here
BAFNAPH.NS vs IPCALAB.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, IPCALAB.BO has a market cap of 418B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while IPCALAB.BO trades at ₹1,631.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas IPCALAB.BO's P/E ratio is 36.60. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to IPCALAB.BO's ROE of +0.15%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to IPCALAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check IPCALAB.BO's competition here
BAFNAPH.NS vs SUVENPHAR.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SUVENPHAR.NS has a market cap of 412.4B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SUVENPHAR.NS trades at ₹1,078.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SUVENPHAR.NS's P/E ratio is 98.90. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SUVENPHAR.NS's ROE of +0.09%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SUVENPHAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SUVENPHAR.NS's competition here
BAFNAPH.NS vs SUVENPHAR.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SUVENPHAR.BO has a market cap of 411.4B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SUVENPHAR.BO trades at ₹1,075.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SUVENPHAR.BO's P/E ratio is 98.29. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SUVENPHAR.BO's ROE of +0.07%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SUVENPHAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SUVENPHAR.BO's competition here
BAFNAPH.NS vs AJANTPHARM.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, AJANTPHARM.BO has a market cap of 371.1B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while AJANTPHARM.BO trades at ₹3,017.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas AJANTPHARM.BO's P/E ratio is 36.62. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to AJANTPHARM.BO's ROE of +0.26%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to AJANTPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check AJANTPHARM.BO's competition here
BAFNAPH.NS vs AJANTPHARM.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, AJANTPHARM.NS has a market cap of 370.9B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while AJANTPHARM.NS trades at ₹3,021.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas AJANTPHARM.NS's P/E ratio is 35.12. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to AJANTPHARM.NS's ROE of +0.26%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to AJANTPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check AJANTPHARM.NS's competition here
BAFNAPH.NS vs JBCHEPHARM.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, JBCHEPHARM.NS has a market cap of 350B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while JBCHEPHARM.NS trades at ₹2,204.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas JBCHEPHARM.NS's P/E ratio is 49.02. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to JBCHEPHARM.NS's ROE of +0.19%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to JBCHEPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check JBCHEPHARM.NS's competition here
BAFNAPH.NS vs JBCHEPHARM.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, JBCHEPHARM.BO has a market cap of 349.7B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while JBCHEPHARM.BO trades at ₹2,202.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas JBCHEPHARM.BO's P/E ratio is 48.98. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to JBCHEPHARM.BO's ROE of +0.19%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to JBCHEPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check JBCHEPHARM.BO's competition here
BAFNAPH.NS vs EMCURE.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, EMCURE.NS has a market cap of 326B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while EMCURE.NS trades at ₹1,750.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas EMCURE.NS's P/E ratio is 35.21. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to EMCURE.NS's ROE of +0.20%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to EMCURE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check EMCURE.NS's competition here
BAFNAPH.NS vs WOCKPHARMA.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, WOCKPHARMA.BO has a market cap of 307.7B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while WOCKPHARMA.BO trades at ₹1,882.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas WOCKPHARMA.BO's P/E ratio is 145.00. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to WOCKPHARMA.BO's ROE of +0.05%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to WOCKPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check WOCKPHARMA.BO's competition here
BAFNAPH.NS vs WOCKPHARMA.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, WOCKPHARMA.NS has a market cap of 307.6B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while WOCKPHARMA.NS trades at ₹1,877.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas WOCKPHARMA.NS's P/E ratio is 144.94. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to WOCKPHARMA.NS's ROE of +0.05%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to WOCKPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check WOCKPHARMA.NS's competition here
BAFNAPH.NS vs PEL.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, PEL.NS has a market cap of 254.9B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while PEL.NS trades at ₹1,124.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas PEL.NS's P/E ratio is 44.24. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to PEL.NS's ROE of +0.02%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to PEL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check PEL.NS's competition here
BAFNAPH.NS vs PPLPHARMA.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, PPLPHARMA.BO has a market cap of 219.1B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while PPLPHARMA.BO trades at ₹168.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas PPLPHARMA.BO's P/E ratio is -66.96. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to PPLPHARMA.BO's ROE of -0.04%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to PPLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check PPLPHARMA.BO's competition here
BAFNAPH.NS vs PPLPHARMA.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, PPLPHARMA.NS has a market cap of 219B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while PPLPHARMA.NS trades at ₹168.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas PPLPHARMA.NS's P/E ratio is -66.94. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to PPLPHARMA.NS's ROE of -0.04%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to PPLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check PPLPHARMA.NS's competition here
BAFNAPH.NS vs NEULANDLAB.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, NEULANDLAB.NS has a market cap of 217.6B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while NEULANDLAB.NS trades at ₹17,167.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas NEULANDLAB.NS's P/E ratio is 59.71. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to NEULANDLAB.NS's ROE of +0.22%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to NEULANDLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check NEULANDLAB.NS's competition here
BAFNAPH.NS vs NEULANDLAB.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, NEULANDLAB.BO has a market cap of 217.6B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while NEULANDLAB.BO trades at ₹17,181.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas NEULANDLAB.BO's P/E ratio is 59.69. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to NEULANDLAB.BO's ROE of +0.22%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to NEULANDLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check NEULANDLAB.BO's competition here
BAFNAPH.NS vs ASTRAZEN.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, ASTRAZEN.BO has a market cap of 209.6B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while ASTRAZEN.BO trades at ₹8,444.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas ASTRAZEN.BO's P/E ratio is 112.06. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to ASTRAZEN.BO's ROE of +0.23%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to ASTRAZEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check ASTRAZEN.BO's competition here
BAFNAPH.NS vs ASTRAZEN.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, ASTRAZEN.NS has a market cap of 208.6B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while ASTRAZEN.NS trades at ₹8,496.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas ASTRAZEN.NS's P/E ratio is 111.51. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to ASTRAZEN.NS's ROE of +0.23%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to ASTRAZEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check ASTRAZEN.NS's competition here
BAFNAPH.NS vs GRANULES.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, GRANULES.NS has a market cap of 189.9B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while GRANULES.NS trades at ₹762.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas GRANULES.NS's P/E ratio is 31.29. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to GRANULES.NS's ROE of +0.14%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to GRANULES.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check GRANULES.NS's competition here
BAFNAPH.NS vs ERIS.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, ERIS.NS has a market cap of 189.2B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while ERIS.NS trades at ₹1,363.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas ERIS.NS's P/E ratio is 30.12. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to ERIS.NS's ROE of +0.19%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to ERIS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check ERIS.NS's competition here
BAFNAPH.NS vs ERIS.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, ERIS.BO has a market cap of 189.2B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while ERIS.BO trades at ₹1,364.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas ERIS.BO's P/E ratio is 30.12. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to ERIS.BO's ROE of +0.19%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to ERIS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check ERIS.BO's competition here
BAFNAPH.NS vs GRANULES.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, GRANULES.BO has a market cap of 186.1B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while GRANULES.BO trades at ₹760.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas GRANULES.BO's P/E ratio is 34.10. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to GRANULES.BO's ROE of +0.14%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to GRANULES.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check GRANULES.BO's competition here
BAFNAPH.NS vs COHANCE.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, COHANCE.NS has a market cap of 162.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while COHANCE.NS trades at ₹430.45.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas COHANCE.NS's P/E ratio is 90.28. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to COHANCE.NS's ROE of +0.06%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to COHANCE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check COHANCE.NS's competition here
BAFNAPH.NS vs COHANCE.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, COHANCE.BO has a market cap of 162.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while COHANCE.BO trades at ₹430.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas COHANCE.BO's P/E ratio is 90.24. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to COHANCE.BO's ROE of +0.06%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to COHANCE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check COHANCE.BO's competition here
BAFNAPH.NS vs CAPLIPOINT.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, CAPLIPOINT.NS has a market cap of 160.5B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while CAPLIPOINT.NS trades at ₹2,237.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas CAPLIPOINT.NS's P/E ratio is 25.08. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to CAPLIPOINT.NS's ROE of +0.21%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to CAPLIPOINT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check CAPLIPOINT.NS's competition here
BAFNAPH.NS vs CAPLIPOINT.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, CAPLIPOINT.BO has a market cap of 160.4B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while CAPLIPOINT.BO trades at ₹2,232.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas CAPLIPOINT.BO's P/E ratio is 25.09. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to CAPLIPOINT.BO's ROE of +0.21%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to CAPLIPOINT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check CAPLIPOINT.BO's competition here
BAFNAPH.NS vs NATCOPHARM.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, NATCOPHARM.BO has a market cap of 155.6B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while NATCOPHARM.BO trades at ₹861.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas NATCOPHARM.BO's P/E ratio is 10.11. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to NATCOPHARM.BO's ROE of +0.17%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to NATCOPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check NATCOPHARM.BO's competition here
BAFNAPH.NS vs NATCOPHARM.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, NATCOPHARM.NS has a market cap of 155.5B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while NATCOPHARM.NS trades at ₹862.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas NATCOPHARM.NS's P/E ratio is 10.96. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to NATCOPHARM.NS's ROE of +0.17%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to NATCOPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check NATCOPHARM.NS's competition here
BAFNAPH.NS vs JUBLPHARMA.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, JUBLPHARMA.NS has a market cap of 151.6B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while JUBLPHARMA.NS trades at ₹966.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas JUBLPHARMA.NS's P/E ratio is 38.11. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to JUBLPHARMA.NS's ROE of +0.06%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to JUBLPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check JUBLPHARMA.NS's competition here
BAFNAPH.NS vs JUBLPHARMA.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, JUBLPHARMA.BO has a market cap of 150.2B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while JUBLPHARMA.BO trades at ₹965.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas JUBLPHARMA.BO's P/E ratio is 37.76. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to JUBLPHARMA.BO's ROE of +0.06%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to JUBLPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check JUBLPHARMA.BO's competition here
BAFNAPH.NS vs APLLTD.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, APLLTD.BO has a market cap of 146.5B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while APLLTD.BO trades at ₹736.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas APLLTD.BO's P/E ratio is 21.71. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to APLLTD.BO's ROE of +0.13%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to APLLTD.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check APLLTD.BO's competition here
BAFNAPH.NS vs APLLTD.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, APLLTD.NS has a market cap of 146.5B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while APLLTD.NS trades at ₹735.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas APLLTD.NS's P/E ratio is 21.71. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to APLLTD.NS's ROE of +0.13%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to APLLTD.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check APLLTD.NS's competition here
BAFNAPH.NS vs GLS.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, GLS.NS has a market cap of 133.1B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while GLS.NS trades at ₹1,086.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas GLS.NS's P/E ratio is 31.50. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to GLS.NS's ROE of +0.21%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to GLS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check GLS.NS's competition here
BAFNAPH.NS vs GLS.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, GLS.BO has a market cap of 133B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while GLS.BO trades at ₹1,085.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas GLS.BO's P/E ratio is 30.23. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to GLS.BO's ROE of +0.09%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to GLS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check GLS.BO's competition here
BAFNAPH.NS vs ALIVUS.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, ALIVUS.NS has a market cap of 123B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while ALIVUS.NS trades at ₹1,030.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas ALIVUS.NS's P/E ratio is 21.81. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to ALIVUS.NS's ROE of +0.18%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to ALIVUS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check ALIVUS.NS's competition here
BAFNAPH.NS vs ALIVUS.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, ALIVUS.BO has a market cap of 122.8B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while ALIVUS.BO trades at ₹1,028.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas ALIVUS.BO's P/E ratio is 21.81. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to ALIVUS.BO's ROE of +0.21%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to ALIVUS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check ALIVUS.BO's competition here
BAFNAPH.NS vs VIYASH.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, VIYASH.NS has a market cap of 109.9B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while VIYASH.NS trades at ₹259.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas VIYASH.NS's P/E ratio is 62.79. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to VIYASH.NS's ROE of +0.09%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to VIYASH.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check VIYASH.NS's competition here
BAFNAPH.NS vs CAPPL.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, CAPPL.BO has a market cap of 109.4B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while CAPPL.BO trades at ₹1,446.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas CAPPL.BO's P/E ratio is 50.30. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to CAPPL.BO's ROE of +0.10%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to CAPPL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check CAPPL.BO's competition here
BAFNAPH.NS vs SHILPAMED.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SHILPAMED.NS has a market cap of 104.1B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SHILPAMED.NS trades at ₹548.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SHILPAMED.NS's P/E ratio is 42.84. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SHILPAMED.NS's ROE of +0.10%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SHILPAMED.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SHILPAMED.NS's competition here
BAFNAPH.NS vs PGHL.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, PGHL.BO has a market cap of 102.9B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while PGHL.BO trades at ₹6,200.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas PGHL.BO's P/E ratio is 31.49. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to PGHL.BO's ROE of +0.59%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to PGHL.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check PGHL.BO's competition here
BAFNAPH.NS vs PGHL.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, PGHL.NS has a market cap of 102.9B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while PGHL.NS trades at ₹6,200.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas PGHL.NS's P/E ratio is 31.44. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to PGHL.NS's ROE of +0.59%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to PGHL.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check PGHL.NS's competition here
BAFNAPH.NS vs STAR.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, STAR.NS has a market cap of 92.7B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while STAR.NS trades at ₹1,012.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas STAR.NS's P/E ratio is 16.66. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to STAR.NS's ROE of +0.20%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to STAR.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check STAR.NS's competition here
BAFNAPH.NS vs STAR.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, STAR.BO has a market cap of 92.7B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while STAR.BO trades at ₹1,011.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas STAR.BO's P/E ratio is 16.65. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to STAR.BO's ROE of +0.20%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to STAR.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check STAR.BO's competition here
BAFNAPH.NS vs AKUMS.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, AKUMS.NS has a market cap of 83.5B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while AKUMS.NS trades at ₹548.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas AKUMS.NS's P/E ratio is 32.71. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to AKUMS.NS's ROE of +0.08%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to AKUMS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check AKUMS.NS's competition here
BAFNAPH.NS vs SUDEEPPHRM.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SUDEEPPHRM.NS has a market cap of 82.4B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SUDEEPPHRM.NS trades at ₹738.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SUDEEPPHRM.NS's P/E ratio is 49.12. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SUDEEPPHRM.NS's ROE of N/A. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SUDEEPPHRM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SUDEEPPHRM.NS's competition here
BAFNAPH.NS vs SPARC.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SPARC.BO has a market cap of 66.1B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SPARC.BO trades at ₹206.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SPARC.BO's P/E ratio is 4.26. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SPARC.BO's ROE of +11.09%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SPARC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SPARC.BO's competition here
BAFNAPH.NS vs SPARC.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SPARC.NS has a market cap of 66.1B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SPARC.NS trades at ₹206.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SPARC.NS's P/E ratio is 4.25. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SPARC.NS's ROE of +11.09%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SPARC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SPARC.NS's competition here
BAFNAPH.NS vs FDC.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, FDC.NS has a market cap of 62.1B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while FDC.NS trades at ₹390.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas FDC.NS's P/E ratio is 22.04. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to FDC.NS's ROE of +0.12%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to FDC.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check FDC.NS's competition here
BAFNAPH.NS vs FDC.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, FDC.BO has a market cap of 62B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while FDC.BO trades at ₹389.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas FDC.BO's P/E ratio is 22.04. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to FDC.BO's ROE of +0.12%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to FDC.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check FDC.BO's competition here
BAFNAPH.NS vs AARTIPHARM.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, AARTIPHARM.NS has a market cap of 55B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while AARTIPHARM.NS trades at ₹622.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas AARTIPHARM.NS's P/E ratio is 31.53. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to AARTIPHARM.NS's ROE of +0.09%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to AARTIPHARM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check AARTIPHARM.NS's competition here
BAFNAPH.NS vs AARTIPHARM.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, AARTIPHARM.BO has a market cap of 54.9B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while AARTIPHARM.BO trades at ₹622.25.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas AARTIPHARM.BO's P/E ratio is 31.46. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to AARTIPHARM.BO's ROE of +0.09%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to AARTIPHARM.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check AARTIPHARM.BO's competition here
BAFNAPH.NS vs SUVEN.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SUVEN.BO has a market cap of 54.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SUVEN.BO trades at ₹257.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SUVEN.BO's P/E ratio is -19.00. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SUVEN.BO's ROE of -1.01%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SUVEN.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SUVEN.BO's competition here
BAFNAPH.NS vs SUVEN.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SUVEN.NS has a market cap of 52.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SUVEN.NS trades at ₹257.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SUVEN.NS's P/E ratio is -19.25. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SUVEN.NS's ROE of -1.01%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SUVEN.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SUVEN.NS's competition here
BAFNAPH.NS vs SHILPAMED.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SHILPAMED.BO has a market cap of 52.1B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SHILPAMED.BO trades at ₹546.15.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SHILPAMED.BO's P/E ratio is 42.80. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SHILPAMED.BO's ROE of +0.10%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SHILPAMED.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SHILPAMED.BO's competition here
BAFNAPH.NS vs SEQUENT.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SEQUENT.BO has a market cap of 50.6B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SEQUENT.BO trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SEQUENT.BO's P/E ratio is 123.41. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SEQUENT.BO's ROE of +0.06%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SEQUENT.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SEQUENT.BO's competition here
BAFNAPH.NS vs SEQUENT.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SEQUENT.NS has a market cap of 50.6B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SEQUENT.NS trades at ₹202.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SEQUENT.NS's P/E ratio is 124.17. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SEQUENT.NS's ROE of +0.06%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to SEQUENT.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SEQUENT.NS's competition here
BAFNAPH.NS vs INNOVACAP.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, INNOVACAP.NS has a market cap of 49.8B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while INNOVACAP.NS trades at ₹905.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas INNOVACAP.NS's P/E ratio is 35.31. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to INNOVACAP.NS's ROE of +0.14%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to INNOVACAP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check INNOVACAP.NS's competition here
BAFNAPH.NS vs BLISSGVS.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, BLISSGVS.NS has a market cap of 44.4B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while BLISSGVS.NS trades at ₹420.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas BLISSGVS.NS's P/E ratio is 34.94. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to BLISSGVS.NS's ROE of +0.12%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to BLISSGVS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check BLISSGVS.NS's competition here
BAFNAPH.NS vs BLISSGVS.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, BLISSGVS.BO has a market cap of 44.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while BLISSGVS.BO trades at ₹419.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas BLISSGVS.BO's P/E ratio is 34.93. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to BLISSGVS.BO's ROE of +0.12%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to BLISSGVS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check BLISSGVS.BO's competition here
BAFNAPH.NS vs GUJTHEM.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, GUJTHEM.NS has a market cap of 43.8B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while GUJTHEM.NS trades at ₹402.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas GUJTHEM.NS's P/E ratio is 93.48. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to GUJTHEM.NS's ROE of +0.17%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to GUJTHEM.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check GUJTHEM.NS's competition here
BAFNAPH.NS vs ORCHPHARMA.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, ORCHPHARMA.BO has a market cap of 42.9B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while ORCHPHARMA.BO trades at ₹850.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas ORCHPHARMA.BO's P/E ratio is 209.34. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to ORCHPHARMA.BO's ROE of +0.02%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to ORCHPHARMA.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check ORCHPHARMA.BO's competition here
BAFNAPH.NS vs ORCHPHARMA.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, ORCHPHARMA.NS has a market cap of 42.7B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while ORCHPHARMA.NS trades at ₹854.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas ORCHPHARMA.NS's P/E ratio is 208.04. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to ORCHPHARMA.NS's ROE of +0.02%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to ORCHPHARMA.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check ORCHPHARMA.NS's competition here
BAFNAPH.NS vs GUFICBIO.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, GUFICBIO.NS has a market cap of 37.8B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while GUFICBIO.NS trades at ₹383.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas GUFICBIO.NS's P/E ratio is 58.86. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to GUFICBIO.NS's ROE of +0.10%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to GUFICBIO.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check GUFICBIO.NS's competition here
BAFNAPH.NS vs GUFICBIO.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, GUFICBIO.BO has a market cap of 37.7B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while GUFICBIO.BO trades at ₹383.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas GUFICBIO.BO's P/E ratio is 58.89. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to GUFICBIO.BO's ROE of +0.10%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to GUFICBIO.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check GUFICBIO.BO's competition here
BAFNAPH.NS vs IOLCP.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, IOLCP.BO has a market cap of 37.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while IOLCP.BO trades at ₹131.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas IOLCP.BO's P/E ratio is 27.01. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to IOLCP.BO's ROE of +0.08%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to IOLCP.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check IOLCP.BO's competition here
BAFNAPH.NS vs IOLCP.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, IOLCP.NS has a market cap of 37.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while IOLCP.NS trades at ₹131.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas IOLCP.NS's P/E ratio is 27.06. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to IOLCP.NS's ROE of +0.08%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to IOLCP.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check IOLCP.NS's competition here
BAFNAPH.NS vs RPGLIFE.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, RPGLIFE.NS has a market cap of 34.6B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while RPGLIFE.NS trades at ₹2,105.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas RPGLIFE.NS's P/E ratio is 30.01. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to RPGLIFE.NS's ROE of +0.21%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to RPGLIFE.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check RPGLIFE.NS's competition here
BAFNAPH.NS vs RPGLIFE.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, RPGLIFE.BO has a market cap of 34.5B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while RPGLIFE.BO trades at ₹2,094.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas RPGLIFE.BO's P/E ratio is 29.94. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to RPGLIFE.BO's ROE of +0.21%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to RPGLIFE.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check RPGLIFE.BO's competition here
BAFNAPH.NS vs NOVARTIND.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, NOVARTIND.BO has a market cap of 33.4B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while NOVARTIND.BO trades at ₹1,344.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas NOVARTIND.BO's P/E ratio is 35.85. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to NOVARTIND.BO's ROE of +0.12%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to NOVARTIND.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check NOVARTIND.BO's competition here
BAFNAPH.NS vs AARTIDRUGS.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, AARTIDRUGS.NS has a market cap of 33.4B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while AARTIDRUGS.NS trades at ₹375.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas AARTIDRUGS.NS's P/E ratio is 17.13. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to AARTIDRUGS.NS's ROE of +0.14%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to AARTIDRUGS.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check AARTIDRUGS.NS's competition here
BAFNAPH.NS vs AARTIDRUGS.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, AARTIDRUGS.BO has a market cap of 33.4B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while AARTIDRUGS.BO trades at ₹374.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas AARTIDRUGS.BO's P/E ratio is 17.13. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to AARTIDRUGS.BO's ROE of +0.14%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to AARTIDRUGS.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check AARTIDRUGS.BO's competition here
BAFNAPH.NS vs NOVARTIND.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, NOVARTIND.NS has a market cap of 33.4B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while NOVARTIND.NS trades at ₹1,348.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas NOVARTIND.NS's P/E ratio is 35.84. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to NOVARTIND.NS's ROE of +0.12%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to NOVARTIND.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check NOVARTIND.NS's competition here
BAFNAPH.NS vs SOLARA.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SOLARA.BO has a market cap of 25.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SOLARA.BO trades at ₹595.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SOLARA.BO's P/E ratio is -316.72. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SOLARA.BO's ROE of -0.01%. Regarding short-term risk, BAFNAPH.NS is less volatile compared to SOLARA.BO. This indicates potentially lower risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SOLARA.BO's competition here
BAFNAPH.NS vs SOLARA.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, SOLARA.NS has a market cap of 25.3B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while SOLARA.NS trades at ₹594.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas SOLARA.NS's P/E ratio is -316.20. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to SOLARA.NS's ROE of -0.01%. Regarding short-term risk, BAFNAPH.NS is less volatile compared to SOLARA.NS. This indicates potentially lower risk in terms of short-term price fluctuations for BAFNAPH.NS.Check SOLARA.NS's competition here
BAFNAPH.NS vs UNICHEMLAB.BO Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, UNICHEMLAB.BO has a market cap of 25.1B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while UNICHEMLAB.BO trades at ₹375.90.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas UNICHEMLAB.BO's P/E ratio is 9.96. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to UNICHEMLAB.BO's ROE of +0.10%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to UNICHEMLAB.BO. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check UNICHEMLAB.BO's competition here
BAFNAPH.NS vs UNICHEMLAB.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, UNICHEMLAB.NS has a market cap of 25.1B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while UNICHEMLAB.NS trades at ₹377.85.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas UNICHEMLAB.NS's P/E ratio is 9.96. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to UNICHEMLAB.NS's ROE of +0.10%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to UNICHEMLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check UNICHEMLAB.NS's competition here
BAFNAPH.NS vs MOREPENLAB.NS Comparison June 2026
BAFNAPH.NS plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, BAFNAPH.NS stands at 4.6B. In comparison, MOREPENLAB.NS has a market cap of 23.5B. Regarding current trading prices, BAFNAPH.NS is priced at ₹188.00, while MOREPENLAB.NS trades at ₹48.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
BAFNAPH.NS currently has a P/E ratio of 41.36, whereas MOREPENLAB.NS's P/E ratio is 24.78. In terms of profitability, BAFNAPH.NS's ROE is +0.12%, compared to MOREPENLAB.NS's ROE of +0.08%. Regarding short-term risk, BAFNAPH.NS is more volatile compared to MOREPENLAB.NS. This indicates potentially higher risk in terms of short-term price fluctuations for BAFNAPH.NS.Check MOREPENLAB.NS's competition here